JOSEPH M HAGGERTY M.D. NPI 1013098870

NPI Details

Joseph M Haggerty, M.D. is a hematology and oncology internal medicine in Rockville, MD with 43 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Joseph M Haggerty, M.D. NPI is 1013098870. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: VIRGINIA COMMONWEALTH UNIVERSITY, SCHOOL OF MEDICINE
Graduation Year:1982

The provider's business location address is:

9707 MEDICAL CENTER DR
SUITE 300
ROCKVILLE, MD
ZIP 20850-348
Phone: (301) 424-6231
Fax: (301) 294-4648

The NPI 1013098870 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Uric acid level, blood (HCPCS:84550)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Glutamyltransferase (liver enzyme) level (HCPCS:82977)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Unclassified drugs (HCPCS:J3490)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)

The enumeration date for this NPI number is 10/18/2006 and was last updated on 6/9/2010.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.